Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,906 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Benmebarek MR, Cadilha BL, Herrmann M, Lesch S, Schmitt S, Stoiber S, Darwich A, Augsberger C, Brauchle B, Rohrbacher L, Oner A, Seifert M, Schwerdtfeger M, Gottschlich A, Rataj F, Fenn NC, Klein C, Subklewe M, Endres S, Hopfner KP, Kobold S. Benmebarek MR, et al. Among authors: klein c. Leukemia. 2021 Aug;35(8):2243-2257. doi: 10.1038/s41375-020-01109-w. Epub 2021 Jan 7. Leukemia. 2021. PMID: 33414484 Free PMC article.
Response to: monoclonal antibodies targeting CD20.
Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, Hopfner KP, Umaña P, Niederfellner G. Klein C, et al. MAbs. 2013 May-Jun;5(3):337-8. doi: 10.4161/mabs.24108. Epub 2013 Mar 14. MAbs. 2013. PMID: 23493087 Free PMC article. No abstract available.
A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
Castoldi R, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, Scheuer W, Venturi M, Klein C, Niederfellner G, Sustmann C. Castoldi R, et al. Among authors: klein c. Oncogene. 2013 Dec 12;32(50):5593-601. doi: 10.1038/onc.2013.245. Epub 2013 Jul 1. Oncogene. 2013. PMID: 23812422 Free PMC article.
Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.
Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger JC, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner G, Klein C, Bourquin C, Endres S. Kobold S, et al. Among authors: klein c. J Natl Cancer Inst. 2014 Nov 24;107(1):364. doi: 10.1093/jnci/dju364. Print 2015 Jan. J Natl Cancer Inst. 2014. PMID: 25424197
TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.
Castoldi R, Schanzer J, Panke C, Jucknischke U, Neubert NJ, Croasdale R, Scheuer W, Auer J, Klein C, Niederfellner G, Kobold S, Sustmann C. Castoldi R, et al. Among authors: klein c. Protein Eng Des Sel. 2016 Oct;29(10):467-475. doi: 10.1093/protein/gzw037. Epub 2016 Aug 29. Protein Eng Des Sel. 2016. PMID: 27578890 Free PMC article.
Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.
Yasuhiro T, Sawada W, Klein C, Kozaki R, Hotta S, Yoshizawa T. Yasuhiro T, et al. Among authors: klein c. Leuk Lymphoma. 2017 Mar;58(3):699-707. doi: 10.1080/10428194.2016.1201567. Epub 2016 Aug 9. Leuk Lymphoma. 2017. PMID: 27684575
High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
Rataj F, Jacobi SJ, Stoiber S, Asang F, Ogonek J, Tokarew N, Cadilha BL, van Puijenbroek E, Heise C, Duewell P, Endres S, Klein C, Kobold S. Rataj F, et al. Among authors: klein c. Br J Cancer. 2019 Jan;120(1):79-87. doi: 10.1038/s41416-018-0341-1. Epub 2018 Nov 15. Br J Cancer. 2019. PMID: 30429531 Free PMC article.
3,906 results